Sign in
Taking people in United StatesPhase 1

Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers

Key facts

Who runs it
Yale University
Where
New Haven, United StatesSee the 2 sites
Trial code
Status
Recruiting
Phase
Phase 1
People taking part
63 people, planned
Started
1 Jul 2024
Expected to end
31 May 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Mavoglurant
Record updated
21 August 2026

Who can take part

Age
21 years to 50 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (19)Hide the full registry criteria

Who can take part

  • Ages 21-50 (The lower limit is to avoid offering alcohol to individuals below the drinking age of 21. The upper age is determined by experience recruiting for our prior studies)
  • Ability to read English at 6th grade level or higher
  • Meet DSM-V criteria for moderate or severe Alcohol Use Disorder (AUD)
  • Average weekly alcohol consumption of 30-70 standard drinks for men and 20-65 drinks for women. The lower limits are consistent with the lower sex-specific cut-offs defining high-risk drinking based on World Health Organization Risk Levels (WHO, 2000); the upper limits are designed to avoid recruiting participants whose drinking is likely to exceed the number of drinks available in the Alcohol Drinking Paradigm (ADP)

Who cannot take part

  • Positive urine drug screens at more than 1 baseline appointment for opiates, cocaine, benzodiazepines and barbiturates
  • Regular use of psychoactive drugs, except for individuals on a stable dose of an antidepressant for at least 2 months
  • Subjects who have taken any investigational drug within 4 weeks of the anticipated date of the first study dose
  • Individuals who report heavy drinking days in the 2 days prior to their intake appointment but have a negative ethyl glucuronide (EtG) test to rule out subjects who are misrepresenting their drinking history
  • Meet current Diagnostic and Statistical Manual v.5 (DSM-V) criteria for substance use disorder, except for tobacco use disorder or mild cannabis use disorder
  • Psychotic or other severe psychiatric disorders as determined by clinical evaluation (Structured Clinical Interview for DSM-V; SCID). Note that if a subject endorses any harm/risk behaviors (e.g. suicidal/homicidal risk) a licensed clinician will be consulted immediately
  • Medical conditions that would contraindicate the consumption of alcohol or use of mavoglurant
  • Neurological trauma or disease, delirium or hallucinations, or clinically significant or unstable medical conditions, including uncontrolled hypertension or diabetes, or significant cardiac, pulmonary, renal, hepatic, endocrine, or other systemic diseases, which in the opinion of the study physician and Principal Investigator, may put the patient at risk because of participation in the study
  • Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scores of 8 or greater or a history of significant repeated alcohol withdrawals to reduce the likelihood of withdrawal symptomatology if subjects reduce their drinking
  • Clinically significant abnormalities in screening laboratories, including aspartate aminotransferase (AST) >3 times upper limit of normal (ULN); alanine aminotransferase (ALT) > 3 times ULN; total bilirubin >1.5 times ULN; serum creatinine >2.0 times ULN
  • Individuals who are seeking alcohol treatment or have been in alcohol treatment within the past 6 months
  • Women who are pregnant or nursing
  • Participants who refuse to use a reliable method of birth control
  • Subjects who report disliking spirits will be excluded because hard liquor will be provided during the ADP
  • Subjects who have donated blood within the past 6 weeks

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Alcohol consumption or heavy drinker or alcohol use disorder

This trial is currently available in United States.

  • Connecticut Mental Health Center (SAC and SATU)New Haven, United StatesContact: Thomas B Liss, BSTaking people
  • Yale New Haven HospitalNew Haven, United StatesContact: Suchitra Krishnan-Sarin, PhDTaking people

About the trial

What the trial wants to find out

The purpose of this research study is to find out about the effects of a drug called mavoglurant on alcohol consumption.

The 2 groups in the trial

  • Mavoglurant 1st / Placebo 2ndTreatment being tested

    Participants randomized to the Mavoglurant 1st Arm will take a single dose of 200mg mavoglurant in the morning, prior to their 1st lab session. Then after a 5-8 day washout period, participants will have their 2nd lab session where they will take a matching placebo in the morning prior to the 2nd lab session.

    Treatment: Mavoglurant

  • Placebo 1st / Mavoglurant 2ndTreatment being tested

    Participants randomized to the Placebo 1st Arm will take a matching placebo in the morning, prior to their 1st lab session. Then after a 5-8 day washout period, participants will have their 2nd lab session where they will take a single dose of 200mg mavoglurant in the morning, prior to their 2nd lab session.

    Treatment: Mavoglurant

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT06136195, who can take part
Record updated
21 August 2026